MetaCap

Alnylam Pharmaceuticals (ALNY) vs Elanco Animal Health (ELAN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elanco Animal Health (ELAN) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 15.7% versus a loss of 67.0%. Over five years, ELAN leads with a -14.8% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $12.87 billion), about 1.5 times the size.

On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (14.5x vs 19.9x for Elanco Animal Health). Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -4.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALNY-67.04%ELAN+15.69%
+25%-23%-71%
Nov 21, 20251 yearNov 20, 2026
ALNY-20.54%ELAN-19.84%
+178%+46%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALNY versus ELAN key metrics
MetricALNYELAN
Share price$143.82$25.74
Market cap$19.26B$12.87B
1-day change-2.71%-2.09%
YTD return-63.83%+13.74%
1-year return-67.04%+15.69%
5-year return-23.72%-14.82%
P/E ratio (TTM)7.26—
Forward P/E14.5119.91
EPS (TTM)$19.80$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.71B$4.71B
Revenue growth (YoY)+65.19%+6.22%
Net income (latest FY)$313.75M$-232.00M
Gross margin81.77%54.99%
Operating margin13.51%—
Net margin8.45%-4.92%
52-week high$479.79$27.98
52-week low$143.40$19.40
Distance from 52-week high-70.02%-8.01%
Analyst consensusbuybuy
Avg. price target upside+101.10%+20.44%
Average volume2.09M5.32M
Shares outstanding133.94M499.83M
Employees2,5009,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELAN has outperformed ALNY by 82.7 percentage points over the past year.
  • Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -4.9 cents for Elanco Animal Health.
  • Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +6.22%).

About Alnylam Pharmaceuticals

ALNY stock →

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees

About Elanco Animal Health

ELAN stock →

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.

Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees

ALNY vs ELAN FAQ

Which is bigger, Alnylam Pharmaceuticals or Elanco Animal Health?

Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $12.87B for Elanco Animal Health (ELAN).

Which stock has performed better over the past year, ALNY or ELAN?

ELAN returned +15.69% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.

Are Alnylam Pharmaceuticals and Elanco Animal Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons